Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Breast Cancer

Interventions

DRUG

Fluzoparib

DRUG

Everolimus

DRUG

Fulvestrant

DRUG

Abemaciclib

Trial Locations (1)

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06561022 - Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping | Biotech Hunter | Biotech Hunter